Atuka are delighted to share that the The Michael J. Fox Foundation for Parkinson’s Research has committed $1.5 million in grant funding to support preclinical research of Kannalife Sciences, Inc.‘s KLS-13019, a synthetic cannabinoid therapeutic which offers great promise for Parkinson’s disease (PD). KLS-13019 has a dual mechanism that can address both neuroinflammation and impaired mitochondrial health, two pathological mechanisms associated with PD.

This grant represents a major milestone in Kannalife’s research efforts, and Atuka is proud to have contributed its expertise in Parkinson’s disease toward developing both the funding proposal and the study protocol to validate this deeply interesting molecule. Atuka’s team—led by Tom Johnston and Patrick Howson, working with our colleague Chi Wang Ip of University Hospital Würzburg—are looking forward to undertaking this multi-year project to validate this unique compound’s therapeutic potential for Parkinson’s. Atuka is always keen to work with collaborators on grant submissions for studies that expand the frontiers of therapeutic development.

+ Follow Atuka on LinkedIn